Search research articles
Contact Us
Filters
Showing results (261-270 of 271) with videos related to
Page
of 28
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
August 26, 2019
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability
Charles G Clark, Karen A Rossi, James R Corte, et al.
Journal of Medicinal Chemistry
|
May 28, 2020
Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species
Wu Yang, Yufeng Wang, Amy Lai, et al.
Journal of Medicinal Chemistry
|
August 26, 2009
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity
Claudio Mapelli, Sesha I Natarajan, Jean-Philippe Meyer, et al.
Journal of Medicinal Chemistry
|
October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
Journal of Medicinal Chemistry
|
September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
Andrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry
|
December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
James R Corte, Donald J P Pinto, Tianan Fang, et al.
Journal of Medicinal Chemistry
|
November 2, 2007
Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180)
Jun Li, Stephanie Y Chen, James J Li, et al.
Journal of Medicinal Chemistry
|
November 5, 2013
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties
Bruce A Ellsworth, Philip M Sher, Ximao Wu, et al.
Journal of Medicinal Chemistry
|
January 24, 2017
Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode
Elizabeth A Jurica, Ximao Wu, Kristin N Williams, et al.
Journal of Medicinal Chemistry
|
January 10, 2018
Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists
Jun Shi, Zhengxiang Gu, Elizabeth Anne Jurica, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 271) with videos related to
Sort By:
Page
of 28
Bioorganic & Medicinal Chemistry Letters
|
August 26, 2019
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability
Charles G Clark, Karen A Rossi, James R Corte, et al.
Journal of Medicinal Chemistry
|
May 28, 2020
Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species
Wu Yang, Yufeng Wang, Amy Lai, et al.
Journal of Medicinal Chemistry
|
August 26, 2009
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity
Claudio Mapelli, Sesha I Natarajan, Jean-Philippe Meyer, et al.
Journal of Medicinal Chemistry
|
October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
Journal of Medicinal Chemistry
|
September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
Andrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry
|
December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
James R Corte, Donald J P Pinto, Tianan Fang, et al.
Journal of Medicinal Chemistry
|
November 2, 2007
Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180)
Jun Li, Stephanie Y Chen, James J Li, et al.
Journal of Medicinal Chemistry
|
November 5, 2013
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties
Bruce A Ellsworth, Philip M Sher, Ximao Wu, et al.
Journal of Medicinal Chemistry
|
January 24, 2017
Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode
Elizabeth A Jurica, Ximao Wu, Kristin N Williams, et al.
Journal of Medicinal Chemistry
|
January 10, 2018
Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists
Jun Shi, Zhengxiang Gu, Elizabeth Anne Jurica, et al.
Page
of 28